Current
Research in
Ophthalmology >>

A Phase 3, randomized, double-masked, parallel-assignment study of intravitreal bevasiranib sodium, administered every 8 or 12 weeks as maintenance therapy following three injections of Lucentis® compared with Lucentis® monotherapy every 4 weeks in patients with Exudative Age-Related Macular Degeneration (AMD) - ACU301B

Principal Investigator

Richard Rosen, MD

Enrollment Status

Completed

Objective

To evaluate the efficacy of intravitreal bevasiranib sodium as maintenance therapy for Age-Related Macular Degeneration following initiation of anti-VEGF therapy with 3 doses of Lucentis®

Contact Information

Julie Paa, CRC
(212) 979-4672

Katy Tai, CR Manager
(212) 979-4251

Home > Current Research > Clinical Trials in Ophthalmology > A PHASE 3, RANDOMIZED, DOUBLE-MASKED, PARALLEL-ASSIGNMENT STUDY OF INTRAVITREAL BEVASIRANIB SODIUM, ADMINISTERED EVERY 8 OR 12 WEEKS AS MAINTENANCE THERAPY FOLLOWING THREE INJECTIONS OF LUCENTIS® COMPARED WITH LUCENTIS® MONOTHERAPY EVERY 4 WEEKS IN PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION (AMD) - ACU301B